Movement Alert｜HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress

Market Focus

Yesterday

On September 10, HENGRUI PHARMA fell 3.13% in regular trading, trading at HK$44.5/share, with turnover of HK$51.87 million.

The decline came amid a broad selloff across the pharmaceuticals sector, despite the company announcing that its subsidiary Fujian Shengdi Pharmaceutical received regulatory acceptance from China's NMPA for the marketing application of a GLP-1 class injectable drug indicated for glycemic control in adult type 2 diabetes patients. Phase III data showed the 4mg dose group achieved an HbA1c reduction of 2.67% at week 36, with a favorable safety profile consistent with marketed GLP-1 drugs.

However, continued headwinds weighed on sentiment. The company's H1 results disclosed in August revealed its first half-year revenue decline in four years, with revenue of RMB 15.456 billion falling 1.94% year-over-year. Additionally, prominent fund manager Ge Lan was reported to have reduced her HENGRUI PHARMA position, while JPMorgan's short position in the H-shares rose to 3.72%.

Within the Pharmaceuticals sector, CSPC Pharma fell 4.12%, Fosun Pharma fell 4.57%, Hansoh Pharma fell 3.28%, SBP Group fell 1.78%, and ChinaRes Pharma fell 1.70%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/news/1143529951"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143529951\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143529951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 10:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143529951","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress","media":"Market Focus","content":"<p><p>On September 10, HENGRUI PHARMA fell 3.13% in regular trading, trading at HK$44.5/share, with turnover of HK$51.87 million.</p><p>The decline came amid a broad selloff across the pharmaceuticals sector, despite the company announcing that its subsidiary Fujian Shengdi Pharmaceutical received regulatory acceptance from China's NMPA for the marketing application of a GLP-1 class injectable drug indicated for glycemic control in adult type 2 diabetes patients. Phase III data showed the 4mg dose group achieved an HbA1c reduction of 2.67% at week 36, with a favorable safety profile consistent with marketed GLP-1 drugs.</p><p>However, continued headwinds weighed on sentiment. The company's H1 results disclosed in August revealed its first half-year revenue decline in four years, with revenue of RMB 15.456 billion falling 1.94% year-over-year. Additionally, prominent fund manager Ge Lan was reported to have reduced her HENGRUI PHARMA position, while JPMorgan's short position in the H-shares rose to 3.72%.</p><p>Within the Pharmaceuticals sector, CSPC Pharma fell 4.12%, Fosun Pharma fell 4.57%, Hansoh Pharma fell 3.28%, SBP Group fell 1.78%, and ChinaRes Pharma fell 1.70%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HENGRUI PHARMA Falls 3.13% in Regular Trading, Broad Pharma Sector Selloff Weighs on Shares Despite Drug Application Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-10 10:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 10, HENGRUI PHARMA fell 3.13% in regular trading, trading at HK$44.5/share, with turnover of HK$51.87 million.</p><p>The decline came amid a broad selloff across the pharmaceuticals sector, despite the company announcing that its subsidiary Fujian Shengdi Pharmaceutical received regulatory acceptance from China's NMPA for the marketing application of a GLP-1 class injectable drug indicated for glycemic control in adult type 2 diabetes patients. Phase III data showed the 4mg dose group achieved an HbA1c reduction of 2.67% at week 36, with a favorable safety profile consistent with marketed GLP-1 drugs.</p><p>However, continued headwinds weighed on sentiment. The company's H1 results disclosed in August revealed its first half-year revenue decline in four years, with revenue of RMB 15.456 billion falling 1.94% year-over-year. Additionally, prominent fund manager Ge Lan was reported to have reduced her HENGRUI PHARMA position, while JPMorgan's short position in the H-shares rose to 3.72%.</p><p>Within the Pharmaceuticals sector, CSPC Pharma fell 4.12%, Fosun Pharma fell 4.57%, Hansoh Pharma fell 3.28%, SBP Group fell 1.78%, and ChinaRes Pharma fell 1.70%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1143529951","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143529951","pubTimestamp":1789008515,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 10, HENGRUI PHARMA fell 3.13% in regular trading, trading at HK$44.5/share, with turnover of HK$51.87 million.The decline came amid a broad selloff across the pharmaceuticals sector,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"走势提醒|恒瑞医药常规交易下跌3.13%，尽管药物申请取得进展，但制药板块广泛抛售拖累股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On September 10, HENGRUI PHARMA fell 3.13% in regular trading, trading at HK$44.5/share, with turnover of HK$51.87 million.The decline came amid a broad selloff across the pharmaceuticals sector, despite the company announcing that its subsidiary Fujian Shengdi Pharmaceutical received regulatory acceptance from China's NMPA for the marketing application of a GLP-1 class injectable drug indicated for glycemic control in adult type 2 diabetes patients. Phase III data showed the 4mg dose group achieved an HbA1c reduction of 2.67% at week 36, with a favorable safety profile consistent with marketed GLP-1 drugs.However, continued headwinds weighed on sentiment. The company's H1 results disclosed in August revealed its first half-year revenue decline in four years, with revenue of RMB 15.456 billion falling 1.94% year-over-year. Additionally, prominent fund manager Ge Lan was reported to have reduced her HENGRUI PHARMA position, while JPMorgan's short position in the H-shares rose to 3.72%.Within the Pharmaceuticals sector, CSPC Pharma fell 4.12%, Fosun Pharma fell 4.57%, Hansoh Pharma fell 3.28%, SBP Group fell 1.78%, and ChinaRes Pharma fell 1.70%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}